Fibrotic Valvular Heart Disease Subsequent to Bromocriptine Treatment
- 1 November 2002
- journal article
- case report
- Published by Wolters Kluwer Health in Cardiology in Review
- Vol. 10 (6) , 334-336
- https://doi.org/10.1097/00045415-200211000-00005
Abstract
Ergot alkaloids, such as ergotamine, have been associated with numerous vascular complications and with valvular heart disease. The authors describe a man who developed fibrosis of three heart valves during a 5-year treatment with bromocriptine for Parkinson disease. There were no other plausible causes. To our knowledge, such a side effect has never been described with this drug.Keywords
This publication has 3 references indexed in Scilit:
- Constrictive Pericarditis and Pleuropulmonary Disease Linked to Ergot Dopamine Agonist Therapy (Cabergoline) for Parkinson's DiseaseMayo Clinic Proceedings, 1999
- Mitral Valve Disease Associated With Long-term Ergotamine UseSouthern Medical Journal, 1993
- PLEUROPULMONARY CHANGES DURING LONG-TERM BROMOCRIPTINE TREATMENT FOR PARKINSON'S DISEASEThe Lancet, 1981